Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Resistance to RAF inhibitors (e.g., vemurafenib, dabrafenib) is a significant challenge in treating melanoma.
• Patients with BRAF-mutant melanoma progressing on RAF inhibitors have limited therapeutic options.
• Mutant BRAF splice variants are a common mechanism driving RAF inhibitor resistance.

Purpose of the Study:

• To investigate the role of mutant BRAF splice variants in RAF inhibitor resistance.
• To determine if these splice variants confer a fitness advantage in the presence of RAF inhibitors.
• To explore the downstream signaling effects and therapeutic implications of continued RAF inhibitor treatment in resistant melanoma.

Main Methods:

• Generation of RAF inhibitor-resistant melanoma cell lines in vivo.
• Testing the growth advantage of cells expressing mutant BRAF splice variants with and without RAF inhibitor (PLX4720 analog).
• Analysis of phospho-extracellular signal-regulated kinase (ERK)1/2 levels and response to MEK inhibitor (trametinib).

Main Results:

• Cells expressing distinct mutant BRAF splice variants exhibited enhanced growth in vitro and in vivo when exposed to the RAF inhibitor PLX4720.
• Treatment with PLX4720 resulted in phospho-ERK1/2 levels comparable to untreated parental cells in resistant variants.
• MEK inhibitor trametinib mimicked the fitness benefit observed with PLX4720, indicating pathway involvement.

Conclusions:

• Melanoma cells with mutant BRAF splice variants benefit from defined concentrations of RAF inhibitors.
• Continued RAF inhibitor therapy may be beneficial for certain RAF inhibitor-resistant melanoma cases.
• These findings challenge the conventional approach of drug withdrawal upon resistance development.